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Introduction
Hereditary spastic paraplegia (HSP) is a group of neu-
rodegenerative disorders characterized by progressive
spasticity and weakness of the lower extremities [1]. HSP
is genetically heterogeneous, and more than 20 genetic
types have been identified [1, 2]. Autosomal dominant
HSP (ADHSP) is the most common genetic type of
HSP, accounting for more than 80% of all familial cases.
Six genetic types of uncomplicated ADHSP and two
genetic types of complicated ADHSP have been defined
[1–3]. Mutations have been identified in five genes
causing ADHSP: spastin in SPG4 linked to chromosome
2p, atlastin in SPG3A linked to chromosome 14q, Hsp60
in SPG13 linked to chromosome 2q, kinesin heavy chain
(KIF5A) in SPG10 linked to 12q, and NIPA1 in SPG6
linked to 15q [4–8]. Despite this recent progress, the
molecular pathogenesis of HSP is unknown.
Pathologic changes in HSP are characterized pri-
marily by axonal degeneration that is most pronounced
in the terminal segments of the longest descending
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Abstract Hereditary spastic para-
plegia (HSP) is a genetically hetero-
geneous group of neurodegenerative
disorders characterized by progres-
sive lower extremity weakness and
spasticity. HSP pathology involves
axonal degeneration that is most
pronounced in the terminal segments
of the longest descending (pyrami-
dal) and ascending (dorsal columns)
tracts. In this study, we compared
spinal cord magnetic resonance
imaging (MRI) in 13 HSP patients
with four different types of autoso-
mal dominant hereditary spastic
paraplegia (SPG3A, SPG4, SPG6,
and SPG8) with age-matched con-
trol subjects. The cross-section area
of HSP subjects at cervical level C2
was 59.42±12.57 mm2 and at tho-
racic level T9 was 28.58±5.25 mm2.
Both of these values were less than in
the healthy controls (p<0.001). The
degree of cord atrophy was more
prominent in patients with SPG6
and SPG8 who had signs of severe
cord atrophy (47.60±6.58 mm2 at
C2, 21.40±2.4 mm2 at T9) than in
subjects with SPG3 and SPG4
(66.0±8.94 mm2 at C2, p<0.02;
31.75±2.76 mm2 at T9, p<0.001).
These observations indicate that
spinal cord atrophy is a common
finding in the four genetic types of
HSP. Spinal cord atrophy was more
severe in SPG6 and SPG8 HSP
subjects than in other types of HSP
we studied. This may suggest a dif-
ferent disease mechanism with more
prominent axonal degeneration in
these two types of HSP when com-
pared with HSP due to spastin and
atlastin mutations.
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[9–11]. Spinal cord atrophy has been observed in some
patients with HSP. However, it is unknown whether this
is a constant feature in all types of ADHSP or whether
the degree of axonal degeneration and subsequent spinal
cord atrophy varies among different genetic types of
HSP.
Magnetic resonance imaging (MRI) has been used to
measure spinal cord size in some HSP patients. Dürr
et al. reported mild cervical spinal cord atrophy (not
quantified) on MRI scans in five of 12 studied individ-
uals [12]. Thoracic spinal cord imaging was not reported.
The genetic type of HSP was not known and thus, no
conclusions about the relationship between the types of
ADHSP and the degree of the atrophy could be made
[12]. Krabbe et al. [13] reported smaller anteroposterior
diameters of the thoracic spinal cord in 16 HSP patients
(later shown to be linked to chromosome 2p [14]).
Qualitative analysis of spinal cord MRI studies in these
patients [13, 14] were without significant abnormality,
although two individuals (brothers) were considered by
one radiologist to have mild atrophy of the thoracic
spinal cord [14]. This indicates that quantitative mea-
surements may be needed to appreciate spinal cord
atrophy in HSP and that the presence and degree of
spinal cord atrophy may be variable within a given type
of HSP. Previously, we reported a clinical analysis of an
SPG8 ADHSP family and noted significant spinal cord
atrophy in one affected individual relatively early in the
course of the disease [15]. This prompted us to compare
the degree of spinal cord atrophy among patients with
genetically diverse types of HSP.
Methods
Clinical analysis
We included 13 patients (six men, seven women; average
age 49.3±10.8 years) who met diagnostic criteria for
HSP and consented to participate in this study approved
by the Institutional Review Board at the University of
Michigan. Each subject had subjective complaints of
gait difficulties and a positive family history of similarly
affected relatives, consistent with the autosomal domi-
nant mode of inheritance. They underwent a complete
neurological examination by a neurologist (P.H. or
J.K.F.), and each patient was definitely affected based
on previously published criteria [3]. Information about
age at symptom onset and progression of the disease was
collected from each subject. Severity of the disease was
graded 1–5 according to previously published criteria
[15]. Briefly, grade 1 corresponds to a spastic gait with-
out functional limitation; grade 2 represents an abnor-
mal gait with functional limitations but not requiring
consistent use of an assistive device; a grade 3 gait
requires consistent use of a cane, crutches, or walker or
occasional use of a wheelchair for long distances; grade 4
represents frequent use of a wheelchair (up to 50% of
the time), but the individual is able to walk short dis-
tances using other assistive devices; and grade 5 marks
functional impairment with inability to walk with crut-
ches, with the individual requiring a wheelchair more
than 50% of the time.
Genetic analysis
The genetic type of HSP was determined by genetic
linkage analysis and/or mutation analysis of spastin
and atlastin genes. We included only subjects for whom
the genetic type of ADHSP was known. Linkage
analysis was used to analyze HSP families with a suf-
ficient statistical power to reach a two-point logarithm
of the odds ratio (LOD score) value >3 to establish a
definitive linkage. Linkage to the SPG4 locus (chro-
mosome 2p) was tested using microsatellite markers
D2S352, D2S367, and D2S2351; SPG3 locus (chro-
mosome 14q) D14S584, D14S746, and D14S269; SPG6
(chromosome 15q) D15S118, D15S542, D15S543, and
D15S128; and SPG8 (chromosome 8q) D8S266,
D8S1799, D8S1138, and D8S1179. Genetic linkage
analysis was performed as previously described [16].
Two-point linkage analysis was performed with the
MLINK subroutine of the LINKAGE program using
an autosomal dominant mode of disease inheritance
and disease allele frequency of 0.001 [17]. We assigned
genetic penetrance of 0.90 for LOD score calculations.
Allele frequencies were not calculated from these fam-
ilies; instead, they were considered to be equal. All
exons of spastin and atlastin genes were amplified using
intronic primers as previously published [4, 5]. Poly-
merase chain reaction products were purified through
the Sephadex G-50 columns and sequenced using the
ABI PRISM dRhodamine Terminator Cycle Sequenc-
ing Ready Reaction and the ABI PRISM 3100 Genetic
Analyzer (PE Applied Biosystems, Foster City, CA).
DNA sequences were analyzed using SeqMan software
(DNA Star, Boston, MA).
MRI analysis
Each patient underwent a noncontrast MRI of the brain
and the whole spine utilizing a 1.5-T magnet. The brain
was evaluated with axial and sagittal T1- and T2-
weighted images; the spinal cord was evaluated with
sagittal T1- and T2-weighted images and axial T1-
weighted images. Axial T1 images of the spinal cord
were done at the level of each vertebra and intervertebral
disc space. MR images were transferred to an imaging
workstation for further analysis by a neuroradiologist
(O.P.E. or P.M.) who was blinded to the genetic status
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of each HSP subject. The brain scans were assessed for
the presence of white matter signal abnormalities on T2-
weighted images. The area of the corpus callosum and
the whole supratentorial brain area were measured from
the midsagittal view, and the corpus callosum index was
calculated as previously published [18]. We measured the
cross-sectional area of the spinal cord at the level of C2
and T9 from T1-weighted axial images. Three mea-
surements for each segment were obtained, and an
average value was calculated. We also selected an age-
and gender-matched control group (19 women and 19
men; average age 51.7±13.9 years) who underwent
MRI of the whole spine and had unremarkable neuro-
logic examinations; the most common indication for
neuroimaging in the control group was back and neck
pain. The second control group (19 women and 19 men;
average age 52.3±12.1 years) had normal MRI of the
brain, and the most common indications for neuroi-
maging were headaches. The spinal cord and brain were
analyzed using the same methods as in the HSP group.
The cross-sectional area of the cervical and thoracic
spinal cord and the corpus callosum index were com-
pared using Student’s t-test; an association between
duration of the disease and the spinal cord size was
analyzed using the Spearman rank correlation test.
Results
Demographic characteristics, age at symptom onset,
severity of disease, and results of genetic analyses of all
patients are summarized in Table 1. We studied five
SPG4 patients (one patient from each of five families),
three SPG3A patients (each from different families),
three SPG8 patients (from the same family), and two
SPG6 patients (from the same family). Clinical descrip-
tions of the individuals with SPG3A, SPG6, and SPG8
have been reported previously [5, 15, 19]. The SPG4
HSP patients had clinical features characteristic of
uncomplicated HSP.
All patients had grossly normal MRI of the brain
with the exception of subject 12, who had a remote left
occipital lobe stroke; we did not detect any areas with
increased signal from the deep white matter on T2-
weighted images. Subjects with ADHSP did not have
signs of corpus callosum atrophy, as the corpus callosum
index did not differ between affected patients and heal-
thy age- and gender-matched controls (0.0412±0.011
and 0.0417±0.013, respectively, not statistically signifi-
cant).
MRI of the spinal cord revealed no signs of cord
compression or abnormal cord signal in any patient with
HSP. Each control subject also had a normal MRI of
the spinal cord. The cross-sectional area of HSP subjects
at the cervical level C2 was 59.42±12.57 mm2 and at the
thoracic level was T9 28.58±5.25 mm2. Both of these
values were significantly less than in healthy controls
(85.66±4.25 and 41.0±7.0 mm2, respectively, both
p<0.001). The degree of spinal cord atrophy was much
more prominent in the subgroup of patients with SPG6
and SPG8 who had signs of severe atrophy, even in
mildly affected subjects (47.60±6.58 mm2 at C2,
21.40±2.4 mm2 at T9), compared with HSP subjects
with SPG3 and SPG4 (66.0±8.94 mm2 at C2, p<0.02;
31.75±2.76 mm2 at T9, p<0.001). There was no cor-
relation between the degree of spinal cord atrophy and
duration and severity of the disease in any genetic sub-
type of HSP (Fig. 1a–h).
Table 1 Demographic, clinical, genetic, and radiologic character-
istics of patients with autosomal dominant hereditary spastic
paraplegia. Positions of the point mutations in the atlastin
(SPG3A) and spastin (SPG4) genes are numbered from starting
codons for each gene; all maximum two-point LOD scores are at





























1 SPG3A A941G 45 M 3 4 63 73 33 80
2 SPG3A C833T 54 M 4 5 60 70 33 80
3 SPG3A C833T 34 F 2 4 60 70 28 68
4 SPG4 D2S2351=3.58 41 F 21 3 66 77 35 85
5 SPG4 Ins1348A 58 M 31 5 52 60 27 66
6 SPG4 D2S2325=3.08 52 F 31 3 75 87 33 80
7 SPG4 D2S367=4.26 38 M 31 3 75 87 33 80
8 SPG4 D2S352=3.25 43 F 32 3 77 90 32 78
9 SPG6 D15S128=8.72 36 F 24 3 42 49 23 56
10 SPG6 D15S128=8.72 57 M 39 5 39 45 22 54
11 SPG8 D8S1179=5.51 57 F 43 3 52 60 24 59
12 SPG8 D8S1179=5.51 71 M 50 5 52 60 20 49
13 SPG8 D8S1179=5.51 55 F 41 4 53 62 18 44
aNormal controls: C2 cross-sectional area 85.66±4.25 mm2; T9 cross-sectional area 41.0±7.0 mm2
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Discussion
Our MRI data indicate that spinal cord atrophy is a
common finding in all four analyzed types of ADHSP:
SPG3A, SPG4, SPG6, and SPG8. Each affected indi-
vidual had a smaller cross-sectional spinal cord area than
the age- and gender-matched controls. Spinal cord atro-
phy wasmore pronounced in the thoracic cord than in the
cervical cord. Even though our MRI method did not al-
low us to separately analyze the size of various descend-
ing and ascending spinal cord tracts, the presence of a
more marked atrophy in the thoracic segment suggests
that the detected spinal cord atrophy is predominantly
due to the degeneration of the descending (pyramidal
tract) spinal cord tracts innervating the lower extremities.
Further analysis of our MRI data also indicates dif-
ferences among various types of ADHSP. Early and
severe spinal cord atrophy appears to be limited to SPG6
and SPG8 and was not seen in patients with SPG4 and
SPG3A. Even though the number of patients with var-
ious genetic types of ADHSP is relatively small, this
difference was so robust that it reached statistical sig-
nificance. SPG6 and SPG8 are relatively rare, and all
studied subjects were from the same families; thus,
additional studies are necessary to establish whether this
is a constant feature of these subtypes of ADHSP.
However, our preliminary MRI data suggest that the
degree of axonal loss is most prominent in these two
types of ADHSP.
The degree of atrophy did not correlate with the
duration or the severity of disease. Patients with AD-
HSP due to atlastin mutations tend to have an onset of
symptoms at an early age, and indeed, all studied indi-
viduals with SPG3A had an onset of symptoms before
the age of 5 years and, consequently, had the longest
duration of disease within our cohort of patients; how-
ever, they were also significantly disabled and required a
wheelchair for a significant amount of time [5]. The
degree of spinal cord atrophy was the mildest in this type
of ADHSP, suggesting that axonal dysfunction may
occur also without significant axonal loss.
We also detected signs of spinal cord atrophy in pa-
tients with the most common type of ADHSP, SPG4 that
is caused by mutations in spastin. Krabbe et al. studied 16
patients with ADHSP later linked to chromosome 2p [13,
14]. They did not find significant differences from the age-
and gender-matched controls in the cross-sectional spinal
cord area in the cervical or thoracic segments. The only
Fig. 1 Different degrees of cord atrophy in various types of
autosomal dominant hereditary spastic paraplegia. a Cervical cord
of subject 3 with SPG3A. b Thoracic cord of subject 3 with
SPG3A. c Cervical cord of subject 4 with SPG4. d Thoracic cord of
subject 4 with SPG4. e Cervical cord of subject 9 with SPG6. f
Thoracic cord of subject 9 with SPG6. g Cervical cord of subject 11
with SPG8. h Thoracic cord of subject 11 with SPG8
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difference detected was a smaller anteroposterior diame-
ter of the spinal cord in HSP patients; however, the sig-
nificance of this change is unclear, as it did not affect the
cross-sectional area of the spinal cord. Moreover, the
authors of this study did not provide complete demo-
graphic and clinical data other than the ranges of age and
duration of symptoms (between 24 and 61 years and
between 4 and 31 years, respectively); thus, it is unclear
whether the discrepancies between our results and theirs
may be due to the differences in patient age or disease
severity. The intra- and interfamilial variability in pa-
tients with SPG4 is well known [4, 20]. This may be one
potential explanation for the lack of spinal cord atrophy
in Krabbe et al.’s group of patients.
Analysis of the brain did not reveal any constant
abnormalities that would distinguish the patients with
HSP from the control group. We did not find signs of
atrophy of the corpus callosum, as the callosal index
was very similar between the patients and the age- and
gender-matched controls. Atrophy of the corpus callo-
sum is a frequent finding in patients with autosomal
recessive HSP linked to chromosome 15q13–q15 [21, 22].
Krabbe et al. also suggested that a mild atrophy of the
corpus callosum was a feature of their SPG4 patients
[13]. However, our data do not support that the corpus
callosum is atrophied in ADHSP.
In summary, this study reports spinal cord atrophy
among different genetic types of ADHSP and suggests
that different disease mechanisms may cause various
types of ADHSP. Some types, for example SPG6 and
SPG8, are associated with severe and early spinal cord
atrophy, whereas others, such as SPG3A and SPG4,
have a marked axonal dysfunction with relatively less
prominent spinal cord atrophy.
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